Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$37.46 USD

37.46
3,663,909

+0.65 (1.77%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $37.44 -0.02 (-0.05%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat

by Zacks Equity Research

Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.

    Zacks Equity Research

    Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat

    by Zacks Equity Research

    Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.

      Zacks Equity Research

      Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View

      by Zacks Equity Research

      Celgene Corporation (CELG) beat earnings and revenue estimates in the second quarter and upped view.

        Zacks Equity Research

        GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance

        by Zacks Equity Research

        Glaxo's (GSK) second-quarter earnings beat estimates, while revenues miss the same. The company cuts its core 2017 earnings growth at CER, with no Advair generics launched this year.

          Zacks Equity Research

          Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View

          by Zacks Equity Research

          Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.

            Zacks Equity Research

            Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up

            by Zacks Equity Research

            Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.

              Zacks Equity Research

              What's in the Cards for Exelixis (EXEL) in Q2 Earnings?

              by Zacks Equity Research

              Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.

                Zacks Equity Research

                Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab

                by Zacks Equity Research

                Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.

                  Zacks Equity Research

                  Vertex (VRTX) Triple Combination CF Studies Data Positive

                  by Zacks Equity Research

                  Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.

                    Zacks Equity Research

                    Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt

                    by Zacks Equity Research

                    Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.

                      Zacks Equity Research

                      Agenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session

                      by Zacks Equity Research

                      Agenus Inc. (AGEN) moved big last session, as its shares rose over 8% on the day.

                        Zacks Equity Research

                        Arena Announces Secondary Stock Worth $150M (revised)

                        by Zacks Equity Research

                        Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.

                          Zacks Equity Research

                          Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit

                          by Zacks Equity Research

                          Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.

                            Zacks Equity Research

                            Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

                            by Zacks Equity Research

                            Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

                              Zacks Equity Research

                              BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug

                              by Zacks Equity Research

                              BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada.

                                Zacks Equity Research

                                Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform

                                by Zacks Equity Research

                                We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.

                                  Zacks Equity Research

                                  Why Exelixis (EXEL) Could Be an Impressive Growth Stock

                                  by Zacks Equity Research

                                  Exelixis (EXEL) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

                                    Zacks Equity Research

                                    Arena Announces Secondary Stock Offering of 150M Shares

                                    by Zacks Equity Research

                                    Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.

                                      David Bartosiak headshot

                                      Five Scorching Hot Stocks Screaming Higher

                                      by David Bartosiak

                                      Five Zacks Rank #1 (Strong Buy) stocks at 52-week highs pushing even higher

                                        Zacks Equity Research

                                        Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

                                        by Zacks Equity Research

                                        Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

                                          Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners

                                            Brian Bolan headshot

                                            Best Stocks For The Second Half of 2017

                                            by Brian Bolan

                                            A look at some stocks that are expected to show some good growth in the back half of the year.

                                              Zacks Equity Research

                                              AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

                                              by Zacks Equity Research

                                              AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

                                                Zacks Equity Research

                                                Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session

                                                by Zacks Equity Research

                                                Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares rise over 12% on the day

                                                  Zacks Equity Research

                                                  Top Ranked Momentum Stocks to Buy for June 27th

                                                  by Zacks Equity Research

                                                  Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 27th: